Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Expanded access is temporarily not available for this treatment.
Sponsor:
Collaborators:
Guangdong General Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Information provided by:
Shanghai Chest Hospital
ClinicalTrials.gov Identifier:
NCT01297101
First received: February 15, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted

February 15, 2011
February 15, 2011
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
A National, Multi Center, Randomized, Open-label, Phase II Trial of Tarceva Versus Combination of Gemcitabine Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N1,N2 NSCLC With Activating EGFR Mutation in Exon 19 or 21

The aim of this study is to investigate the efficacy and safety of Tarceva versus combination of Gemcitabine plus Cisplatin as neoadjuvant treatment in patients with stage IIIA-N1,N2 NSCLC with EGFR activating mutation in exon 19 or 21.

Concurrent Chemoradiation therapy remain the standard treatment for stage IIIA disease, but its treatment-related life threaten toxicity limit its use for those patients.

Tarceva monotherapy have been demonstrated a significant improvement in overall survival and disease progression free survival when used for the treatment of patients with metastatic NSCLC, after failure of at least one prior chemotherapy regimen. It is well tolerated without the side effects usually associated with chemotherapy.

Based on the encouraging results reported from the SLCG phase II study reported the efficacy of Tarceva as first line treatment for metastatic NSCLC with EGFR mutation patients would prolong overall survival, delay disease progression and be well tolerated, mOS reached 27 months, ORR reached 71%. Besides, with different mechanism and more tolerable than chemo, Tarceva may provide an important treatment alternative for local advanced pts with EGFR mutation.

Expanded Access
Not Provided
Not Provided
Non-small Cell Lung Cancer
Drug: Erlotinib
150mg/qd, on day 15-28 of each 28 day cycle.
Other Name: Tarceva
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Temporarily not available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Pathologically diagnosed of non-small cell lung cancer
  • Diagnosed as stage IIIA-NI, N2, except for T4N1M0
  • The diagnosis standard of N1 or N2 is as below:
  • The short axis of N1 lymph node of Stage IIIA-N1 must be ≥ 10 mm on Computed Tomography, and the Standard Uptake Value (SUV) on PET-CT of N1 lymph node must be > 2.5

Exclusion Criteria:

  • Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab)
  • Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy)
  • Resection of primary malignancy
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01297101
ML25268(C-TONG1101)
Not Provided
Lu Shun / Profess, Shanghai Chest Hospital
Shanghai Chest Hospital
  • Guangdong General Hospital
  • Shanghai Pulmonary Hospital, Shanghai, China
Not Provided
Shanghai Chest Hospital
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP